Intraoperative Detection of Disappearing Colorectal Liver Metastases as a Predictor of Residual Disease

Journal of Gastrointestinal Surgery

Volumn 16, Issue 4, 2012, Pages 806-814

  Ferrero, Alessandro ^a   Langella, Serena ^a   Russolillo, Nadia ^a   Vigano', Luca ^a   Tesoriere, Roberto Lo ^a   Capussotti, Lorenzo ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

Chemotherapy pathological response; Disappearing liver metastases; Intraoperative ultrasonography

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

AGED; ARTICLE; CARCINOMA; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; ORGANOPLATINUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84858705382     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1810-5     Document Type: Article

References (40)

1. Nordlinger B, Sorbye H, Glimelius B, et. al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
2. Adam R, Wicherts DA, de Haas RJ, et. al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835.
3. Ribero D, Wang H, Donadon M et. al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-7.
4. Folprecht G, Gruenberger T, Bechstein WO, et. al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
5. Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17: 492-501.
6. Chun YS, Vauthey JN, Boonsirikamchai P, et. al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-2344.
7. Adam R, Wicherts DA, de Haas RJ, et. al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635-41.
8. Rubbia-Brandt L, Giostra E, Brezault C, et. al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
9. Blazer DG III, Kishi Y, Maru DM, et. al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
10. Dy GK, Krook JE, Green EM, et. al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: Results from Intergroup N9741. J Clin Oncol 2007; 25: 3469-3474.
11. Benoist S, Brouquet A, Penna C, et. al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945.
12. Elias D, Goere D, Boige V, et. al. Outcome of posthepatectomy missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194.
13. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250: 935-942.
14. Auer RC, White RR, Kemeny NE, et. al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509.
15. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned? J Gastrointest Surg 2010; 14: 1691-700.
16. Carpenter S, Fong Y. Management of disappearing colorectal hepatic metastases. Adv Surg 2010; 44: 269-79.
17. Thomay AA, Charpentier KP. Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy. J Surg Oncol 2010; 102: 1002-8.
18. Choti MA, Kaloma F, de Oliveira ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM. Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg 2008; 143: 29-34.
19. The Brisbane 2000 Terminology of Liver Anatomy and Resection. Terminology Committee of The International Hepato-Pancreato-Biliary Association. HPB 2000; 2: 333-339.
20. Kleiner DE, Brunt EM, van Natta M, et. al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 4: 1313-1321.
21. Robinson PJA. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009; 19: 1752-1762.
22. Znajda TL, Hayashi S, Horton PJ, et. al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 2006; 10: 483-9.
23. Foroutani A, Garland AM, Berber E, et. al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. Arch Surg 2000; 135: 933-8.
24. Torzilli G, Makuuchi M. Intraoperative ultrasonography in liver cancer. Surg Oncol Clin N Am 2003; 12: 91-103.
25. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77: 2008-2011.
26. Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12: 722-7.
27. Vauthey JN, Pawlik TM, Ribero D, et. al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
28. Angliviel B, Benoist S, Penna C, et. al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 2009; 16: 1247-53.
29. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11: 1112-1119.
30. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145: 340-5.
31. Lubezky N, Metser U, Geva R, et. al. The role and limitations of 18-fluoro-2-deoxy-d -glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007; 11: 472-8.
32. Bipat S, van Leewen MS, Comans EFI, Pijl MEJ, Bossuyt BMM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging and PET for diagnosis-meta-analysis. Radiology 2005; 237: 123-31.
33. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31.
34. Kulemann V, Schima W, Tamandl D, et. al. Preoperative detection of colorectal liver metastases: MDCT or MRI? Eur J Radiol 2011; 79: e1-6.
35. Conlon R, Jacobs M, Dasgupta D, Lodge JP. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J of Ultrasound 2003; 16: 21-16.
36. van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, Choti MA. The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative ultrasonography. Arch Surg 2010; 147: 661-7.
37. Torzilli G, Del Fabbro D, Palmisano A et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9: 1148-53.
38. Leen E, Ceccotti P, Moug SJ et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg 2006; 243: 236-40.
39. Torzilli G, Botea F, Procopio F et al. Use of contrast-enhanced intraoperative ultrasonography during liver surgery for colorectal cancer liver metastases-its impact on operative outcome. Analysis of a prospective cohort study. Eur J Cancer 2008; 6: 16-23.
40. Kishi Y, Zorzi D, Contreras CM, et. al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17: 2870-6.